Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

• Market Cap: ₹22.31B
• Dividend Yield: 0.28%
• Average Volume (3M): 104.36K
• Price to Earnings (P/E): 18.6
• Beta (1Y): 1.42
• Revenue Growth: 7.51%
• EPS Growth: 71.81%
• Country: IN
• Employees: 831
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.20
• Shares Outstanding: 105,788,970
• 10 Day Avg. Volume: 77,644
• 30 Day Avg. Volume: 104,358
• PEG Ratio: 1.37
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.56
• P/FCF Ratio: 42.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ₹232.00 ▲(60.28% Upside)
• Action: Reiterated Date: 01/07/26
• Date: Action: Reiterated 01/07/26

The score is driven primarily by solid financial fundamentals—especially a strong, low-leverage balance sheet and improving profitability—supported by a clear technical uptrend. Valuation is reasonable on earnings but offers limited support from a very low dividend yield.

Positive Factors

Strong balance sheet

A high equity ratio and low leverage provide durable financial flexibility, allowing the company to fund regulatory compliance, absorb cyclical demand in generics, and pursue selective capex or M&A without relying heavily on debt. Improving ROE signals better long-term capital efficiency.

Improving margins

Sustained improvement in gross, EBIT and EBITDA margins indicates effective cost control and operational leverage. This enhances cash generation potential and resilience against pricing pressure in generics, supporting reinvestment and consistent profitability over multiple quarters.

Diversified revenue streams

Having finished dosage sales, export contracts and third‑party manufacturing spreads revenue risk across channels and customers. Export and contract manufacturing provide institutional, recurring order flows that help stabilize revenue and scale manufacturing capability over the medium term.

Negative Factors

Variable free cash flow

Inconsistent free cash flow constrains the company’s ability to fund growth initiatives, repay debt, or sustain higher dividends without external financing. Variability likely reflects working capital/tender timing and reduces predictability for long‑term investment planning.

Inconsistent EBITDA performance

Fluctuating EBITDA undermines forecasting and may reflect sensitivity to pricing, input costs, or one‑off items. Persistent volatility in operating profitability can limit capacity to commit to multi‑year expansion plans and may increase scrutiny from institutional counterparties.

Moderate revenue growth

A ~7% top‑line growth rate is modest for a specialty/generics pharma player and may slow scale benefits. If sustained, this pace could limit the firm’s ability to ramp R&D, expand manufacturing capacity, or outgrow competitors in export and tender markets over the next several quarters.

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

How the Company Makes Money

Bliss GVS Pharma makes money primarily by selling pharmaceutical products. Its key revenue streams include (1) sales of finished dosage formulations (e.g., tablets and other formulations) under its own marketing and distribution channels, (2) export sales to international markets (including supply to institutional buyers and tender-based procurement where applicable), and (3) contract manufacturing/third-party manufacturing services for other pharmaceutical marketers, where the company produces finished products and earns manufacturing and supply revenue. Earnings are influenced by product mix (notably its contraceptive/reproductive health portfolio), scale of export orders, regulatory compliance enabling access to specific markets, pricing and competitive dynamics in generics, and the company’s ability to secure repeat orders from distributors and institutional customers. Specific details on major partnerships, customer concentration, or exact revenue split by segment are null.

Bliss Gvs Pharma Limited Financial Statement Overview

Summary

Strong balance sheet (high equity, low leverage, improving ROE) and improving profitability/margins support the score. The main offset is mixed cash flow performance and variable free cash flow growth, suggesting room to improve cash generation.

Income Statement

Bliss Gvs Pharma Limited has shown consistent revenue growth over the years, with a notable increase in gross and net profit margins in the latest year. The EBIT and EBITDA margins have improved, indicating efficient cost management and operational performance. While the revenue growth trajectory is positive, there could be improved consistency in EBITDA performance.

Balance Sheet

The company maintains a strong balance sheet with a high equity ratio and low debt-to-equity ratio, showcasing financial stability and low leverage. The return on equity has seen improvement, reflecting the company's ability to generate profits from shareholders' equity. The company's strong equity position is a key strength.

Cash Flow

The cash flow position has been mixed, with variability in free cash flow growth rates. The operating cash flow to net income ratio indicates a healthy cash conversion cycle, but the free cash flow to net income ratio suggests room for improvement. The company should focus on optimizing capital expenditures to enhance free cash flow.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.60B	8.10B	7.66B	7.47B	7.38B	5.69B
Gross Profit	3.95B	3.96B	2.49B	3.50B	3.47B	2.40B
EBITDA	2.07B	1.27B	1.49B	1.35B	762.37M	1.27B
Net Income	1.10B	842.99M	754.54M	708.59M	150.40M	684.91M
Balance Sheet
Total Assets	14.00B	13.01B	12.14B	11.57B	11.09B	10.77B
Cash, Cash Equivalents and Short-Term Investments	2.01B	1.41B	1.41B	684.11M	1.35B	616.64M
Total Debt	524.91M	881.04M	998.40M	1.02B	1.09B	1.22B
Total Liabilities	2.32B	2.09B	2.11B	2.39B	2.62B	2.49B
Stockholders Equity	11.32B	10.50B	9.67B	8.84B	8.19B	8.08B
Cash Flow
Free Cash Flow	483.04M	298.48M	1.24B	-594.86M	614.77M	548.45M
Operating Cash Flow	775.52M	1.06B	1.52B	343.13M	1.35B	639.69M
Investing Cash Flow	-272.20M	-754.41M	-1.33B	-77.51M	-929.75M	-469.91M
Financing Cash Flow	-448.06M	-303.45M	-208.93M	-249.38M	-237.30M	-207.98M

Bliss Gvs Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 144.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Neutral. The current price of 144.75 is below the 20-day moving average (MA) of 214.25, below the 50-day MA of 196.21, and below the 200-day MA of 166.31, indicating a neutral trend. The MACD of 2.54 indicates Positive momentum. The RSI at 49.56 is Neutral, neither overbought nor oversold. The STOCH value of 49.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLISSGVS	74 Outperform	₹22.31B	18.57	―	0.28%	7.51%	71.81%
WINDLAS	71 Outperform	₹15.36B	27.93	―	0.71%	19.34%	9.32%
JAGSNPHARM	67 Neutral	₹12.23B	28.83	―	1.24%	24.60%	153.56%
SYNCOMF	64 Neutral	₹11.09B	17.72	―	―	56.41%	90.24%
HESTERBIO	61 Neutral	₹11.85B	38.81	―	0.44%	-3.84%	86.82%
BAJAJHCARE	53 Neutral	₹9.90B	20.91	―	0.24%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bliss Gvs Pharma Limited Corporate Events

Bliss GVS Pharma Adds New Step-Down Subsidiary in DR Congo to Deepen African Reach

Bliss GVS Pharma Limited has expanded its African presence through its Singapore-based wholly owned subsidiary, Bliss GVS International PTE Ltd, which has incorporated a new step-down wholly owned subsidiary, THERALIFE PHARMA RDC PRIVATE LIMITED, in Kinshasa–Gombe, Democratic Republic of the Congo. The new entity, established with a modest initial share capital of USD 1,000, signals the company’s continued strategic push into emerging healthcare markets, potentially strengthening its distribution, local market access, and positioning within the regional pharmaceutical landscape, though detailed operational plans and financial implications have not yet been disclosed.